Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.57 |
| ▸ | AGXT | P21549 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 5/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649272 | 0.86 | IDO1 (0.44) | IDO1AGXTSLC6A4TAAR1 | |
| SCHEMBL682849 | 0.83 | IDO1 (0.53) | IDO1AGXTSLC6A4APPMAOB | |
| SCHEMBL6525289 | 0.83 | IDO1 (0.53) | IDO1AGXTSLC6A4APPMAOB | |
| SCHEMBL7492817 | 0.83 | IDO1 (0.53) | IDO1AGXTSLC6A4APPMAOB | |
| SCHEMBL12502485 | 0.83 | IDO1 (0.53) | IDO1AGXTSLC6A4APPMAOB | |
| SCHEMBL14545522 | 0.83 | ADRB2 (0.55) | IDO1AGXTSLC6A4APPMAOB | |
| SCHEMBL18504830 | 0.83 | POLB (0.53) | — | |
| SCHEMBL10819596 | 0.82 | MAOB (0.60) | APPMAOB | |
| SCHEMBL12134040 | 0.82 | ACACB (0.39) | IDO1AGXTSLC6A4 | |
| SCHEMBL28885907 | 0.82 | IDO1 (0.52) | IDO1AGXTSLC6A4APPMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219894-A1 | DISUBSTITUTED ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR SUPPRESSING CANCER GROWTH COMPRISING SAME AS ACTIVE INGREDIENT | ONECUREGEN CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230183164-A1 | Synthesis of Vinyl Cyclobutyl Intermediates | AMGEN INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183164-A1 | Synthesis of Vinyl Cyclobutyl Intermediates | AMGEN INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230174496-A1 | Synthesis of Vinylic Protected Alcohol Intermediates | AMGEN INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174496-A1 | Synthesis of Vinylic Protected Alcohol Intermediates | AMGEN INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230167130-A1 | Ring Closing Synthesis of Macrocyclic MCL-1 Inhibitor Intermediates | AMGEN INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167130-A1 | Ring Closing Synthesis of Macrocyclic MCL-1 Inhibitor Intermediates | AMGEN INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| WO-2021226009-A1 | SYNTHESIS OF VINYL CYCLOBUTYL INTERMEDIATES | AMGEN INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20120321855-A1 | PATTERN FORMING METHOD AND RESIST COMPOSITION | FUJIFILM CORPORATION (JP) | 2012-12-20 | — | — | US | disclosed |
| US-20120301817-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM USING THE COMPOSITION AND PATTERN FORMING METHOD | FUJIFILM CORPORATION (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120301817-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM USING THE COMPOSITION AND PATTERN FORMING METHOD | FUJIFILM CORPORATION (JP) | 2012-11-29 | — | — | US | disclosed |
| WO-2012158413-A2 | PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120282548-A1 | PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST FILM | FUJIFILM CORPORATION (JP) | 2012-11-08 | — | — | US | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-1202628-B1 | NOVEL HYPOXANTHINE AND THIOHYPOXANTHINE COMPOUNDS | EURO CELTIQUE SA (LU) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174496-A1 | Synthesis of Vinylic Protected Alcohol Intermediates | MCL1, BCL2A1, BAK1 | IDO1 2038/4885AGXT 3008/4885SLC6A4 4794/4885 |
| US-20230183164-A1 | Synthesis of Vinyl Cyclobutyl Intermediates | MCL1, BCL2A1, BAK1 | IDO1 1712/4885AGXT 3957/4885SLC6A4 4834/4885 |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | IDO1 1065/4885AGXT 4641/4885SLC6A4 370/4885 |
| US-20230167130-A1 | Ring Closing Synthesis of Macrocyclic MCL-1 Inhibitor Intermediates | MCL1, BAK1, BCLAF1 | IDO1 1797/4885AGXT 3595/4885SLC6A4 4725/4885 |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | HLA-DRB1, CD74, HLA-C | IDO1 117/4885AGXT 2405/4885SLC6A4 3307/4885 |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | TBK1, NFKBIA, IKBKB | IDO1 589/4885AGXT 2878/4885SLC6A4 4082/4885 |
| US-20230219894-A1 | DISUBSTITUTED ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR SUPPRESSING CANCER GROWTH COMPRISING SAME AS ACTIVE INGREDIENT | AK2, CS, GOT2 | IDO1 3895/4885AGXT 3384/4885SLC6A4 1441/4885 |
| US-20120282548-A1 | PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST FILM | RAD51, RER1, RXRA | IDO1 4596/4885AGXT 1844/4885SLC6A4 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.